- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
37
37 companies
Madrigal Pharmaceuticals
Market Cap: US$12.2b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$545.36
7D
1.6%
1Y
89.7%
Axsome Therapeutics
Market Cap: US$12.5b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$249.76
7D
2.0%
1Y
130.4%
Syndax Pharmaceuticals
Market Cap: US$2.0b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$23.24
7D
6.3%
1Y
165.6%
Ardelyx
Market Cap: US$1.3b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.38
7D
5.5%
1Y
20.1%
Forum Markets
Market Cap: US$90.0m
A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.
FRMM
US$5.70
7D
5.0%
1Y
-28.6%
Alnylam Pharmaceuticals
Market Cap: US$41.8b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$321.59
7D
6.8%
1Y
1.3%
Capricor Therapeutics
Market Cap: US$1.3b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$22.22
7D
-7.7%
1Y
118.5%
Zevra Therapeutics
Market Cap: US$825.8m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$14.44
7D
0.7%
1Y
25.0%
Aldeyra Therapeutics
Market Cap: US$137.5m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$2.23
7D
4.7%
1Y
-48.5%
CG Oncology
Market Cap: US$6.1b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$69.20
7D
-2.6%
1Y
166.6%
Arcutis Biotherapeutics
Market Cap: US$3.3b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$27.67
7D
5.5%
1Y
101.1%
BioStem Technologies
Market Cap: US$64.9m
Engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
BSEM
US$3.29
7D
-0.5%
1Y
-72.6%
Insmed
Market Cap: US$24.2b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$112.84
7D
5.8%
1Y
17.4%
Vera Therapeutics
Market Cap: US$2.9b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$42.96
7D
0.1%
1Y
86.8%
SIGA Technologies
Market Cap: US$269.0m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.67
7D
0.8%
1Y
-45.8%
NewAmsterdam Pharma
Market Cap: US$4.1b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
NAMS
US$36.99
7D
9.1%
1Y
84.8%
Belite Bio
Market Cap: US$6.1b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
BLTE
US$157.69
7D
2.4%
1Y
162.3%
Rezolute
Market Cap: US$515.0m
A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
RZLT
US$4.97
7D
-4.4%
1Y
0%
Praxis Precision Medicines
Market Cap: US$8.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$323.95
7D
-3.2%
1Y
592.8%
Unicycive Therapeutics
Market Cap: US$143.1m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
UNCY
US$5.43
7D
15.8%
1Y
9.3%
Citius Pharmaceuticals
Market Cap: US$16.7m
A biopharmaceutical company, focuses on the development and commercialization of critical care products.
CTXR
US$0.58
7D
-3.5%
1Y
-69.8%
Iovance Biotherapeutics
Market Cap: US$1.9b
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
IOVA
US$4.35
7D
4.6%
1Y
145.8%
TriSalus Life Sciences
Market Cap: US$264.7m
Engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
TLSI
US$4.07
7D
-10.5%
1Y
-21.3%
Rhythm Pharmaceuticals
Market Cap: US$7.7b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$114.46
7D
3.1%
1Y
75.7%
Aytu BioPharma
Market Cap: US$24.1m
A pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
AYTU
US$2.25
7D
4.7%
1Y
-3.8%
AnaptysBio
Market Cap: US$1.8b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$67.33
7D
-0.3%
1Y
177.6%
Journey Medical
Market Cap: US$198.8m
A commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$6.75
7D
-4.7%
1Y
-2.5%
Mirum Pharmaceuticals
Market Cap: US$7.4b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$128.31
7D
9.6%
1Y
155.2%
Zymeworks
Market Cap: US$1.8b
A biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases.
ZYME
US$26.72
7D
2.2%
1Y
106.3%
Gyre Therapeutics
Market Cap: US$663.4m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$7.01
7D
6.4%
1Y
-13.7%
Fennec Pharmaceuticals
Market Cap: US$371.3m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$10.50
7D
-2.3%
1Y
20.7%
Prothena
Market Cap: US$497.4m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
PRTA
US$9.68
7D
-1.1%
1Y
48.5%
Annexon
Market Cap: US$976.5m
A clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
ANNX
US$6.43
7D
12.6%
1Y
137.3%
Protagonist Therapeutics
Market Cap: US$8.5b
Operates as a discovery and development company in the United States.
PTGX
US$140.74
7D
14.8%
1Y
183.2%
Alpha Cognition
Market Cap: US$172.0m
A biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
ACOG
US$8.10
7D
12.2%
1Y
-24.1%
Celcuity
Market Cap: US$5.3b
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$115.72
7D
10.6%
1Y
763.6%